Blog

May 5, 2018

Eximis Surgical is Driven to Find a Better Solution for Women

A recent JAMA Surgery article "Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation" in the April 11, 2018 issue highlights the ongoing challenge Eximis Surgical is aiming to solve.

The study looked at over 75,000 patients undergoing hysterectomy from over 600 US hospitals to assess changes in the rates of 30-day major and minor complications for benign gynecologic indications after the FDA's morcellator black box warning in 2014. For women undergoing hysterectomy for uterine fibroids (33.9% of patients) the study found that more women received open hysterectomies and had a corresponding increase in complication rates after the black box warning than before. The authors concluded, "the 20% increase in the odds of major and minor complications could translate into a large number of additional complications among the 200,000 hysterectomies performed annually for uterine fibroids in the United States."

This means that more women annually in the U.S. undergoing hysterectomy for benign indications will have a greater risk of experiencing a major complication such as sepsis, pneumonia, deep incisional surgical site infection, acute renal failure, pulmonary embolism, cardiac arrest requiring cardiopulmonary resuscitation, and stroke or cerebrovascular accident with neurological deficit. 

The benefits of minimally invasive surgery are well known, and this study highlights Eximis Surgical's mission to answer the call for a better solution for women.

Posted by Kristin Johnson, CEO and Co-Founder